Spondylitis
Drug research and approvals for spondylitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 153 studies of spondylitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 13 drug trials for it since 2013, and the EU has 6 authorised medicines for it.
- Recruiting worldwide: 153
- Trials authorized in Canada: 13
- FDA orphan approvals: 0
- EU medicines: 6
- CAPN12 Gene Expression as a Molecular DiscriminatorNCT07946497 · Not reported · South Valley University · starts Oct 1, 2026
- A Study of HB0017 Injection in Healthy Volunteers to Evaluate Safety and Tolerability of a Single Subcutaneous…NCT07920861 · Phase 1 · Huabo Biopharm Co., Ltd. · starts Jan 19, 2026
- Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or…NCT07908641 · Phase 1 · Amgen · starts Nov 18, 2026
- Phase Ia Study of MST-931 in Healthy Adult SubjectsNCT07903493 · Phase 1 · Mabsoft Therapeutics (Shanghai) Co., Ltd. · starts Nov 30, 2026
- Retinal Capillary Vessel Density and Foveal Avascular Zone Size in Patients With Psoriatic Arthritis: A Case-Control…NCT07858591 · Not reported · Bursa Yuksek Ihtisas Training and Research Hospital · starts Sep 1, 2026
- Surface Topography and Radiographic Spinal Damage in Radiographic Axial SpondyloarthritisNCT07855393 · Not reported · Ankara Etlik City Hospital · starts Sep 19, 2026
- RENEW Intervention for Axial SpondyloarthritisNCT07836374 · Not applicable · University of Michigan · starts Oct 22, 2026
- Pain Phenotyping of Rheumatic Diseases - An Observational StudyNCT07829497 · Not reported · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · starts Nov 9, 2026
- A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic…NCT07801495 · Phase 2 · Novartis Pharmaceuticals · starts Oct 19, 2026
Approved 9
- CelecoxibCyclooxygenase-2 inhibitor
- EtanerceptTNF-alpha inhibitor
- GolimumabTNF-alpha inhibitor
- IndomethacinCyclooxygenase inhibitor
- NaproxenCyclooxygenase inhibitor
- PenicillamineCopper chelating agent
- SulindacCyclooxygenase inhibitor
- PrednisoneGlucocorticoid receptor agonist
- AceclofenacCyclooxygenase-2 inhibitor
How its trials ended
718 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 183 whose ending is known, 63% met their primary endpoint, 8% missed it and 30% stopped early.
- Completed, result not reported26737%
- Ongoing15421%
- Met its primary endpoint11516%
- Status unknown11416%
- Stopped: other or unclear274%
- Stopped: enrollment or feasibility152%
- Missed its primary endpoint142%
- Stopped: lack of efficacy61%
- Stopped: sponsor or business decision41%
- Stopped: safety2<1%
| Aug 13, 2025 | A phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of tulisokibart in participants with radiographic axial…Tulisokibart (MK-7240) | Merck & Co. (MSD) | Ongoing |
| Sep 3, 2021 | A phase 2 multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CC-99677 in subjects with…BMS-986371 (CC-99677) | Bristol-Myers Squibb | Closed |
| Aug 31, 2020 | A phase 3, randomized, double blind, placebo controlled study to evaluate the efficacy and safety of filgotinib in subjects with active ankylosing spondylitis…Filgotinib | Gilead Sciences | Closed |
| Aug 31, 2020 | A phase 3, randomized, double blind, placebo controlled study to evaluate the efficacy and safety of filgotinib in subjects with active ankylosing spondylitis…Filgotinib | Gilead Sciences | Closed |
| Apr 23, 2018 | A phase 3, randomized, double-blind, placebo-controlled, study of the efficacy and safety of tofacitinib in subjects with active ankylosing spondylitis (AS)Tofacitinib (CP-690,550) | Pfizer | Closed |
| Nov 14, 2017 | A multicenter, open-label, extension study to evaluate the long term safety and efficacy of bimekizumab in subjects with ankylosing spondylitisBimekizumab | UCB | Ongoing |
| Nov 10, 2017 | A randomized, partially-blinded, active-controlled multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017…Cosentyx / GP2017 (adalimumab) | Novartis Pharmaceuticals | Closed |
| Aug 14, 2017 | A multicenter, randomized, double-blind, placebo controlled study evaluating the safety and efficacy of upadacitinib in subjects with active ankylosing…Upadacitinib (ABT-494) | AbbVie | Closed |
| Nov 23, 2016 | A multicenter, phase 2b, randomized, double blind, placebo-controlled, parallel group, dose-ranging study to evaluate the efficacy and safety of bimekizumab in…Bimekizumab | UCB | Ongoing |
| Feb 13, 2015 | A randomized, double-blind, placebo-controlled, phase III multicenter study of subcutaneous secukinumab (150 mg) with and without a subcutaneous loading…Secukinumab (AIN457) | Novartis Pharmaceuticals | Ongoing |
| Jul 26, 2018 | HefiyaAdalimumab · biosimilar | Sandoz GmbH | EMA ↗ |
| May 18, 2018 | ZesslyInfliximab · biosimilar | Sandoz GmbH | EMA ↗ |
| Aug 24, 2017 | ImraldiAdalimumab · biosimilar | Samsung Bioepis NL B.V. | EMA ↗ |
| Sep 8, 2003 | HumiraAdalimumab | AbbVie Deutschland GmbH & Co. KG | EMA ↗ |
| Feb 2, 2000 | EnbrelEtanercept | Pfizer Europe MA EEIG | EMA ↗ |
| Aug 13, 1999 | RemicadeInfliximab | Janssen Cilag International NV | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA